News
PFE
37.01
-1.57%
-0.59
What's Ahead for the 10 Stocks That Have Driven Over 80% of U.S. Market Returns So Far in 2023
NASDAQ · 2h ago
For the First Time Ever, Single-Stock ETFs Soon Will Close
NASDAQ · 12h ago
Seagen shareholders OK acquisition by Pfizer
Seeking Alpha · 14h ago
Eli Lilly partners with XtalPi on AI drug discovery in up to $250M deal
Seeking Alpha · 14h ago
Seagen Stockholders Approve Acquisition By Pfizer For $229 Per Share In Cash
Benzinga · 15h ago
LABU: 2 Requirements For Making Money In This Leveraged Biotech Fund
Seeking Alpha · 20h ago
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
NASDAQ · 20h ago
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
NASDAQ · 21h ago
Pfizer succeeds in Phase 3 trial for hemophilia candidate
Seeking Alpha · 23h ago
Pfizer Says Pivotal Phase 3 BASIS Clinical Trial Of Marstacimab Met Primary Endpoints
NASDAQ · 23h ago
Pyxis Oncology Doses First Subject in Phase 1 Trial of Immunotherapy Antibody Candidate
Pyxis Oncology Doses First Subject in Phase 1 Trial of Immunotherapy Antibody Candidate
MT Newswires · 23h ago
Next set of COVID boosters to target new Omicron variants – WSJ
Seeking Alpha · 23h ago
Pfizer Announced Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial; Said Study Demonstrated Statistically Significant Reduction In Annualized Bleeding Rate Vs Prophylaxis, On-demand Intravenous Regimens
Benzinga · 23h ago
Pfizer's hemophilia therapy reduces bleeding in late-stage study
Reuters · 23h ago
BRIEF-Pfizer Announces Positive Marstacimab Results From Pivotal Phase 3 Hemophilia A And B Trial
Reuters · 23h ago
Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?
Motley Fool · 1d ago
Pfizer Says Phase 3 Trial of Hemophilia Drug Marstacimab Met Primary Endpoints
Pfizer Says Phase 3 Trial of Hemophilia Drug Marstacimab Met Primary Endpoints
MT Newswires · 1d ago
Pfizer: The New Oral Weight Loss Therapy Could Be A Game Changer
Seeking Alpha · 1d ago
LLY, DXCM, or ISRG: Which Healthcare Stock is the Top Stock Pick?
NASDAQ · 1d ago
Should You Pick AbbVie Stock Over LLY?
NASDAQ · 1d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.